Traders sold shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on strength during trading on Thursday. $83.60 million flowed into the stock on the tick-up and $101.44 million flowed out of the stock on the tick-down, for a money net flow of $17.84 million out of the stock. Of all equities tracked, Regeneron Pharmaceuticals had the 0th highest net out-flow for the day. Regeneron Pharmaceuticals traded up $4.82 for the day and closed at $389.52

A number of equities analysts recently weighed in on the stock. Jefferies Group restated a “hold” rating and issued a $444.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 19th. Morgan Stanley decreased their price objective on shares of Regeneron Pharmaceuticals from $436.00 to $415.00 in a report on Friday, April 8th. Wells Fargo & Co. lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Wednesday, April 20th. Brean Capital restated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 12th. Finally, Cowen and Company restated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Sunday, April 17th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $506.34.

The stock has a market cap of $40.81 billion and a P/E ratio of 62.05. The firm has a 50 day moving average price of $368.27 and a 200-day moving average price of $394.82.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported $2.57 earnings per share for the quarter, missing analysts’ consensus estimates of $2.58 by $0.01. The business had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the firm earned $2.88 earnings per share. The business’s quarterly revenue was up 38.0% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals Inc. will post $10.78 earnings per share for the current fiscal year.

In related news, major shareholder Sanofi bought 64,731 shares of the company’s stock in a transaction dated Tuesday, June 14th. The shares were acquired at an average price of $363.86 per share, for a total transaction of $23,553,021.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Plew Daniel P. Van sold 4,413 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, May 18th. The shares were sold at an average price of $385.77, for a total transaction of $1,702,403.01. Following the completion of the sale, the executive vice president now owns 11,381 shares in the company, valued at approximately $4,390,448.37. The disclosure for this sale can be found here.

Other hedge funds recently made changes to their positions in the company. Jennison Associates LLC raised its stake in shares of Regeneron Pharmaceuticals by 4.9% in the fourth quarter. Jennison Associates LLC now owns 2,016,027 shares of the biopharmaceutical company’s stock valued at $1,094,441,000 after buying an additional 93,894 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Regeneron Pharmaceuticals by 5.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 136,447 shares of the biopharmaceutical company’s stock valued at $74,078,000 after buying an additional 7,316 shares during the period. Principal Financial Group Inc. raised its stake in shares of Regeneron Pharmaceuticals by 2.1% in the fourth quarter. Principal Financial Group Inc. now owns 106,583 shares of the biopharmaceutical company’s stock valued at $57,861,000 after buying an additional 2,198 shares during the period. Bank of Montreal Can raised its stake in shares of Regeneron Pharmaceuticals by 4.8% in the fourth quarter. Bank of Montreal Can now owns 41,944 shares of the biopharmaceutical company’s stock valued at $22,770,000 after buying an additional 1,933 shares during the period. Finally, Schroder Investment Management Group raised its stake in shares of Regeneron Pharmaceuticals by 122.1% in the fourth quarter. Schroder Investment Management Group now owns 25,011 shares of the biopharmaceutical company’s stock valued at $13,578,000 after buying an additional 13,749 shares during the period.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.